HSV thymidine kinase gene therapy - Transgene

Drug Profile

HSV thymidine kinase gene therapy - Transgene

Latest Information Update: 07 Mar 2002

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Nonindustrial source; Transgene
  • Developer Transgene
  • Class Gene therapies
  • Mechanism of Action Thymidine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 07 Mar 2002 Discontinued - Preclinical for Cancer in France (Intratumoural)
  • 07 Jan 2002 No-Development-Reported for Cancer in France (Intratumoural)
  • 10 Mar 1998 Preclinical development for Cancer in France (Intratumoural)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top